Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 27, 2026, 4:25 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: "hormone-sensitive" Clear all
Completed No phase listed Observational Accepts healthy volunteers

Healthy Transitions: Menopause Effect on Obesity, Energy Balance, and Insulin

NCT00412269
View directory record Official record
Conditions
Menopause
Interventions
Not listed
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
47 Years to 52 Years · Female only
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2007
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jan 24, 2016 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 3 Interventional Results available

A Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT02677896
View directory record Official record
Conditions
Metastatic Hormone Sensitive Prostate Cancer
Interventions
Enzalutamide, Placebo
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
34
States / cities
Homewood, Alabama • Anchorage, Alaska • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Sep 27, 2026, 4:25 AM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)

NCT02319837
View directory record Official record
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Interventions
Enzalutamide, Placebo (No longer applicable in Open Label study period), Leuprolide Open Label
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,068 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
77
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Completed No phase listed Observational

Psychobiological Mechanisms of Resilience to Trauma

NCT00069212
View directory record Official record
Conditions
Stress Disorders, Post-Traumatic
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 27, 2026, 4:25 AM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Kegg Fertility Study

NCT06862440
View directory record Official record
Conditions
Fertility
Interventions
Kegg
Device
Lead sponsor
Lady Technologies Inc
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
189 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Not applicable Interventional

Cocoa and Metabolic Health in Prediabetes

NCT02203240
View directory record Official record
Conditions
Prediabetes
Interventions
Cocoa, Placebo
Other
Lead sponsor
Virginia Polytechnic Institute and State University
Other
Eligibility
40 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Blacksburg, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Clinical Safety of a Novel Milk Protein Peptide

NCT01412658
View directory record Official record
Conditions
Drug Safety
Interventions
Hydrolyzed milk protein mixture, Glycerol placebo
Dietary Supplement
Lead sponsor
Ambryx Biotechnology
Industry
Eligibility
35 Years to 60 Years
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Waco, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2011 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 3 Interventional

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis on Background Topical Corticosteroids

NCT06224348
View directory record Official record
Conditions
Dermatitis Atopic
Interventions
Amlitelimab, Placebo, Topical corticosteroids, Topical calcineurin inhibitors
Drug
Lead sponsor
Sanofi
Industry
Eligibility
12 Years and older
Enrollment
643 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
40
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Encino, California + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Primary Intervention With Mucosal Insulin

NCT02620553
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Human Insulin, Oral Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
2 Years to 7 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 19, 2017 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 1 Interventional Results available

Tofacitinib Hypothesis-generating, Pilot Study for Corticosteroid-Dependent Sarcoidosis

NCT03793439
View directory record Official record
Conditions
Sarcoidosis, Pulmonary, Sarcoidosis Lung, Sarcoidosis
Interventions
Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial, Spirometry, RNA Sequencing, Laboratory testing, Corticosteroid, Tofacitinib 5mg [Xeljanz] 1 year open-label extension
Drug · Diagnostic Test · Genetic
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 89 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 17, 2022 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Oral Glucosamine on Insulin and Blood Vessel Activity in Normal and Obese People

NCT00065377
View directory record Official record
Conditions
Obesity, Insulin Resistance
Interventions
Glucosamine Hydrochloride
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2006
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2006 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 3 Interventional Results available

Comparison of SAR342434 to Humalog as the Rapid Acting Insulin in Adult Patients With Type 2 Diabetes Mellitus Also Using Insulin Glargine

NCT02294474
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
SAR342434, Humalog, insulin glargine HOE901
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
505 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
51
States / cities
Foley, Alabama • Muscle Shoals, Alabama • Chandler, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Jan 17, 2018 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Pilot Study to Determine the Effect of a Cobiotic Formulation on the Gastrointestinal Microbiome

NCT01724736
View directory record Official record
Conditions
Pre Diabetic
Interventions
Placebo, NM504:
Drug
Lead sponsor
NuMe Health
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2014
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Sep 27, 2026, 4:25 AM EDT
Active, not recruiting Phase 3 Interventional

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)

NCT04720157
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
177Lu-PSMA-617, 68Ga-PSMA-11, ARDT, ADT
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years · Male only
Enrollment
1,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
70
States / cities
Scottsdale, Arizona • La Jolla, California • Los Angeles, California + 50 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Recruiting Phase 2 Interventional

Study of 18F-FFNP Breast PET/MRI

NCT06086704
View directory record Official record
Conditions
Breast Cancer
Interventions
18F-fluorofuranylnorprogesterone, Positron Emissions Tomography / Magnetic Resonance Imaging, Anastrozole, Blood Sampling, FDA-approved gadolinium-based intravenous contrast agent
Drug · Device · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Completed No phase listed Observational

A Study to Learn About Two Medicines (Apalutamide and Enzalutamide) in People With Metastatic Castration-sensitive Prostate Cancer (mCSPC)

NCT07086651
View directory record Official record
Conditions
Metastatic Castration Sensitive Prostate Cancer (mCSPC), Cancer of the Prostate, Prostate Neoplasms, Prostate Cancer
Interventions
Enzalutamide, Apalutamide
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
1,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2025 · Synced Sep 27, 2026, 4:25 AM EDT
Active, not recruiting Phase 3 Interventional

Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents

NCT03020030
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Pediatric
Interventions
Pegaspargase, Erwinia asparaginase, Cyclophosphamide, CYTARABINE, DASATINIB, DEXAMETHASONE, Dexrazoxane, Doxorubicin, ETOPOSIDE, HYDROCORTISONE, LEUCOVORIN CALCIUM, MERCAPTOPURINE, METHOTREXATE, NELARABINE, Vincristine
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
1 Year to 21 Years
Enrollment
560 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2034
U.S. locations
7
States / cities
Boston, Massachusetts • New Brunswick, New Jersey • Buffalo, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Active, not recruiting Early Phase 1 Interventional

Androgen Receptor Signaling and Prostate-Specific Membrane Antigen Expression

NCT05683964
View directory record Official record
Conditions
Prostate Adenocarcinoma, Prostate Cancer, Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
Interventions
Apalutamide [Erleada], darolutamide [Nubeqa], or enzalutamide [Xtandi], Prostate-Specific Membrane Antigen (PSMA) PET/CT Scan
Drug · Diagnostic Test
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years and older · Male only
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Study to Determine the Effects of Human Growth Hormone and Pioglitazone in Overweight, Prediabetic Adults

NCT00352287
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Impaired Glucose Tolerance
Interventions
Recombinant human growth hormone; pioglitazone
Drug
Lead sponsor
Stanford University
Other
Eligibility
40 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 13, 2006 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Resveratrol on Age-related Insulin Resistance and Inflammation in Humans

NCT01354977
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Insulin Resistance
Interventions
Resveratrol
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
45 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Mar 7, 2022 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 3 Interventional Results available

Safety And Efficacy Evaluation Of Fx-1006a In Patients With V122i Or Wild-Type Transthyretin (TTR) Amyloid Cardiomyopathy

NCT00935012
View directory record Official record
Conditions
ATTR-CM, TTR-CM
Interventions
tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2019
U.S. locations
7
States / cities
Atlanta, Georgia • Chicago, Illinois • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2021 · Synced Sep 27, 2026, 4:25 AM EDT
Active, not recruiting Not applicable Interventional

Evaluating the Influence of Diet-induced Weight Loss on Fat (Adipose) Tissue's Insulin Sensitivity and Testosterone Synthesis in Women With Overweight or Obesity, Insulin Resistance, and Hyperandrogenemia

NCT06998238
View directory record Official record
Conditions
Overweight and Obesity, Hyperandrogenemia, Insulin Resistance
Interventions
Mediterranean-based, carbohydrate restricted, calorie reduced diet
Behavioral
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
21 Years to 45 Years · Female only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effect of Vitamin D3 Supplementation on Insulin Resistance and Cardiovascular Risk Factors in Obese Adolescents

NCT00858247
View directory record Official record
Conditions
Obesity
Interventions
Vitamin D3
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
12 Years to 18 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated May 19, 2014 · Synced Sep 27, 2026, 4:25 AM EDT
Completed Phase 2 Interventional Results available

Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS

NCT03703492
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma in Situ - Category
Interventions
(18F)FES, Gadobenate dimeglumine
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older · Female only
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 11, 2025 · Synced Sep 27, 2026, 4:25 AM EDT